Bi­o­lu­mi­nes­cence Ven­tures makes it of­fi­cial with $477M in as­sets for ear­ly-stage biotech com­pa­nies

While the name Bi­o­lu­mi­nes­cence Ven­tures has emerged as an in­vestor in var­i­ous biotech fund­ing an­nounce­ments since at least last May, the ven­ture firm of­fi­cial­ly emerged from stealth on Wednes­day, un­veil­ing $477 mil­lion in as­sets.

Led by Kou­ki Ha­rasa­ki, a for­mer se­nior part­ner at An­dreessen Horowitz, Bi­o­lu­mi­nes­cence has al­ready put mon­ey in­to ear­ly-stage biotechs in Mass­a­chu­setts like Take­da-backed cell ther­a­py start­up En­so­ma, neu­ro-fo­cused Nido Bio­sciences, im­munother­a­py de­vel­op­er Surge Ther­a­peu­tics, and the Cal­i­for­nia-based clin­i­cal-stage ge­net­ic med­i­cines com­pa­ny Re­Code Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER